Keywords: astrazeneca, 4th-qtr, profit, leaps, firm, admits, thin
AstraZeneca's 4th-qtr profit leaps 30% but firm admits thin pipeline
Article | 13 February 2006
Anglo-Swedish pharmaceutical major AstraZeneca reported a strong set of fourth-quarter and full-year 2005 results, which were broadly in line with analysts' ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
